Search results for: 'Well owners and testing'
- Did you mean
- well owners ad testing
- Related search terms
- AND (SELECT (CASE WHEN (3989=1399) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,3989) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (4327=4327) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,4327) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (1509=3753) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,1509) END) FROM DUAL) IS NULL-- wUvH
- AND (SELECT 1827 FROM (SELECT(SLEEP(20)))zydf)
- wellness and beauty united arab emirates
-
05 Oct 2018  |  North America  |  Market Research
US Point-of-Care Testing Infectious Disease Market, Forecast to 2022
CLIA Waived Molecular POCT, Coupled with Upcoming Diseases Like Sepsis, Lyme Disease, New Strains of Influenza—H1, H3, and H7, will Drive Growth
Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...
$1,500.00
Special Price $1,125.00 save 25 %
-
30 Jun 2021  |  North America  |  Market Research
US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities
Telegenetic Counseling to Revolutionize Access to Patient Care
In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...
$2,450.00
Special Price $1,837.50 save 25 %
-
12 Sep 2016  |  North America  |  Market Research
Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests
Discover the Perfect Assay Price Point to Remain Competitive
The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...
$1,500.00
Special Price $1,125.00 save 25 %
-
14 Feb 2017  |  North America  |  Market Research
Trends, Opportunities, and Future of the Global Pharma Extractables and Leachables Testing Market
Growing Prominence of Single Use Technologies and Biologics Market Driving Growth
This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020. The pharma E&L testing market is ...
$1,500.00
Special Price $1,125.00 save 25 %
-
30 Dec 2022  |  North America  |  Market Research
Trends and Growth Indicators for Physician Offices/labs in Decentralized Testing and Services
Personalized Diagnostics Are at the Cusp of Transformational Growth
Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...
$2,450.00
Special Price $1,837.50 save 25 %
-
16 Nov 2022  |  North America  |  Market Research
Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025
Demand for High Sensitivity Point-of-Care Testing Enhance Growth Potential
Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as signif...
$4,950.00
Special Price $3,712.50 save 25 %
-
14 Mar 2022  |  North America  |  Market Outlook
Next-generation Diagnostics Outlook, 2022
Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth
In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...
$4,950.00
Special Price $3,712.50 save 25 %
-
19 Sep 2023  |  North America  |  Market Research
Growth Opportunities for Clinical Laboratory Services in Asia-Pacific
Proliferation of High-end Specialized Testing and Interconnected Lab Networks Fuel Growth Potential
Clinical labs are the foundation of the healthcare ecosystem. This research overviews the Asia-Pacific (APAC) clinical laboratory services industry for the period 2022–2028. Country-specific and vertical-specific forecasts are provided from 2023 to 2028 using a base year of 2022. Frost & Sullivan focused on APAC following various events unfolding f...
$4,950.00
Special Price $3,712.50 save 25 %
-
29 Dec 2025  |  North America  |  Market Research
United States Clinical Laboratory Services Growth Opportunities, Forecast 2030
Fueled by Specialty Testing Expansion, Digital Workflow Innovation, and Value-Based Healthcare Demands
The clinical laboratory testing industry will continue to experience growth in testing volumes due to the aging of the US population, patient awareness of the benefits of laboratory testing, test cost reductions, the development of advanced and specialized tests for disease detection and management, the growing awareness of early detection and prev...
$4,950.00 -
28 Feb 2022  |  North America  |  Market Research
United States Clinical Laboratory Services Growth Opportunities
Advanced Molecular Diagnostics and At-Home Testing are Growth Prerequisites
The United States spends more than $3 trillion—nearly 18% of GDP—on healthcare, a massive sector. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population (16.9% in 2020); chronic disease burden; regulatory challenges; integration across the care continuum; migration to val...
$2,450.00
Special Price $1,837.50 save 25 %